bla
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
April 2, 2024Research and Development AstraZeneca, Daiichi Sankyo, FDA, Oncology, bla, breast cancer
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan (Dato-Dxd) has been accepted in …
FDA accepts BLA for Regeneron’s linvoseltamab for Priority Review
February 22, 2024Medical Communications FDA, Oncology, Regeneron, bla, priority review
Regeneron Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for …
FDA accepts Teva asthma drug for review
June 15, 2015Sales and Marketing AstraZeneca, GlaxoSmithKline’s mepolizumab, Teva, benralizumab, bla, cinquil, reslizumab
Teva’s investigational biologic for the treatment of inadequately controlled asthma in patients with elevated blood eosinophils, Cinquil, has been accepted …
Latest content
